Lovage

Metadata

Approved Indications

Commission E (Germany)

• Approved: Irrigation therapy for:
  • Inflammatory diseases of the lower urinary tract
  • Prevention of kidney gravel (Nierengruess)
• Also: Dyspeptic complaints (adjunctive carminative)
• Commission E contraindication: No irrigation therapy in cases of edema due to limited cardiac or renal function

ESCOP

• No monograph: ESCOP has not published a standalone monograph for Levisticum officinale radix

EMA/HMPC

• Traditional Use: Traditional herbal medicinal product used to increase the amount of urine to achieve flushing of the urinary tract as an adjuvant in minor urinary complaints
• Based on traditional use criteria (at least 30 years of medicinal use, including 15+ years within the EU)
• Adults and adolescents over 12 years of age
• The EMA assessment report (EMA/HMPC/71049/2007) concluded that the benefit/risk assessment for Levisticum officinale preparations is positive
• Also included in the European Union herbal monograph on Species diureticae (diuretic tea blends)

Agreement/Disagreement

• Commission E and EMA/HMPC are in broad agreement on the urinary tract irrigation indication
• Commission E is more expansive, including dyspeptic complaints as an additional indication
• EMA/HMPC grants only “traditional use” registration — no “well-established use” designation exists
• ESCOP has not issued a monograph, leaving a gap in the European regulatory triad
• US/Anglophone: Not recognized in mainstream medicine; lovage is known primarily as a culinary herb rather than a medicinal one outside German-speaking Europe

Conditions Treated

Primary Indications

• Irrigation therapy for inflammatory diseases of the lower urinary tract (cystitis, urethritis)
• Prevention of kidney gravel and renal calculi (adjunctive)
• Minor urinary complaints (dysuria, frequency, urgency) as an aquaretic adjuvant
• Dyspeptic complaints: Flatulence, bloating, mild digestive discomfort (Commission E)

As Component of Canephron N (BNO 1045)

Lovage root is one of three herbs in Canephron N (Bionorica SE), a fixed combination phytopharmaceutical containing:

• Lovage root (Levisticum officinale)
• Rosemary leaves (Rosmarinus officinalis)
• Centaury herb (Centaurium erythraea)

Canephron N is one of the most widely prescribed urological phytopharmaceuticals in Europe and is used for:

• Treatment and prophylaxis of uncomplicated urinary tract infections (uUTIs)
• Adjunctive therapy in acute and recurrent cystitis
• Post-surgical UTI prophylaxis (e.g., after midurethral sling procedures)
• Supportive treatment in urinary stone disease (metaphylaxis)
• Gestational urinary tract infections (with caution)

The product is attributed diuretic, spasmolytic, anti-inflammatory, antioxidative, antibacterial, and nephroprotective effects.

Traditional European Use

Lovage has been cultivated and used medicinally in Europe since antiquity. The Greeks and Romans employed it as both a seasoning and a medicine. During the medieval period, Benedictine monks cultivated lovage in monastery physic gardens; it was one of 28 herbs in St. Hildegard of Bingen’s basic medical kit and appeared in the famous St. Gall monastery garden plan. In German folk medicine, the colloquial name “Maggikraut” (Maggi herb) reflects its continued importance as both a culinary and medicinal plant.

Mechanism of Action

Primary Mechanisms

1. Aquaretic / Diuretic Effect

   • Lovage root acts as an aquaretic — a diuretic that increases urine volume without significant electrolyte loss
   • The essential oil constituents are believed to mediate the aquaretic activity
   • Increased urine flow mechanically flushes bacteria, inflammatory mediators, and small calculi from the urinary tract
   • This underpins the irrigation therapy concept (Durchspuelungstherapie) central to its European therapeutic use

2. Spasmolytic Activity

   • Phthalides, particularly ligustilide and 3-butylphthalide, demonstrate smooth muscle relaxation
   • Ligustilide has demonstrated vasorelaxant effects on cardiovascular vessels and myorelaxation of smooth muscle in vitro
   • Spasmolytic action on intestinal smooth muscle accounts for the carminative effect in dyspeptic complaints
   • Spasmolytic action on urinary tract smooth muscle may relieve dysuria and colicky pain from renal gravel

3. Anti-inflammatory Activity

   • Essential oil components and phthalides contribute to anti-inflammatory effects
   • The combination product BNO 2103 (Canephron N extract) has been shown to alleviate inflammatory pain in experimental cystitis and prostatitis models (PMID: 31257118)
   • May reduce inflammation in urinary tract epithelium

4. Antimicrobial Activity

   • Ligustilide exhibits growth inhibitory activity against E. coli (MIC = 4 mg/mL) and S. aureus (MIC = 1 mg/mL)
   • Butylidenephthalide shows antibacterial activity against E. coli and S. aureus (MIC = 4 mg/mL)
   • Clinically, the antimicrobial effect is considered supportive rather than primary

Key Bioactive Compounds

• Phthalides (major pharmacologically active group):
  • Z-Ligustilide (24-62% of essential oil): Principal bioactive marker; spasmolytic, anti-inflammatory, antimicrobial
  • 3-Butylphthalide: Spasmolytic, sedative in animal models
  • E- and Z-Butylidenephthalide: Antimicrobial activity
  • Senkyunolide: Minor phthalide constituent
• Furanocoumarins:
  • Bergapten, psoralen: Photosensitizing agents (safety concern, see below)
  • Xanthotoxin (methoxsalen), isopimpinellin, pimpinellin
• Simple coumarins: Umbelliferone, apterin, scopoletin
• Phenolic acids: Chlorogenic acid, caffeic acid, ferulic acid (antioxidant)
• Essential oil terpenoids: beta-Phellandrene, alpha-terpinyl acetate
• Polyacetylenes: (+)-Falcarindiol (chemo- and thermolabile)
• Vitamin C (minor)

European Pharmacopoeia Standard

• Levistici radix: minimum 0.4% essential oil (Ph. Eur.)
• Ligustilide content is the primary quality marker for the essential oil fraction

Clinical Evidence Summary

Standalone Clinical Evidence for Lovage Root

• Very limited: No large randomized controlled trials exist for lovage root as a monotherapy
• The evidence base is overwhelmingly traditional and pharmacological rather than clinical-trial-derived
• Both Commission E and EMA/HMPC approvals rest on long-standing traditional use combined with pharmacological plausibility
• The EMA assessment explicitly acknowledges that clinical data are insufficient for “well-established use” status

Pharmacological Studies (Lovage Root)

• In vitro: Spasmolytic, antimicrobial, and anti-inflammatory effects of phthalides confirmed
• In vivo (animal): Diuretic/aquaretic effects demonstrated; sedative effects of phthalides in mice
• Antibacterial activity of isolated phthalides against uropathogens (E. coli, S. aureus) confirmed in vitro (PMID: 33232705)
• Phthalide characterization studies have elucidated the chemical composition of the essential oil (PMID: 17402120)

Canephron N (BNO 1045) — Combination Product Evidence

The clinical evidence for lovage root’s therapeutic role is best supported through the Canephron N combination product:

1. Phase III Non-Inferiority Trial vs. Fosfomycin (PMID: 30231252)

   • Design: Double-blind, parallel-group, randomized, multicentre, non-inferiority Phase III trial
   • Population: 659 women (aged 18-70) with acute lower uncomplicated UTIs
   • Intervention: BNO 1045 (2 tablets, 3 times daily for 7 days) vs. fosfomycin trometamol (3g single dose)
   • Primary endpoint: Proportion requiring additional antibiotics, Days 1-38
   • Results: 83.5% of the BNO 1045 group and 89.8% of the fosfomycin group required no additional antibiotics
   • Non-inferiority demonstrated at 15% margin (rate difference: -6.26%; 95% CI -11.99 to -0.53%; p = 0.0014)
   • Conclusion: BNO 1045 has potential to reduce outpatient antibiotic use for uUTIs
   • Registered as NCT02639520

2. Canephron N vs. Ciprofloxacin for Acute Uncomplicated Cystitis (PMID: 30761786)

   • Design: Prospective, randomized study; 160 women aged 18-55
   • Intervention: Canephron N (2 tablets, 3 times daily for 30 days) vs. ciprofloxacin (0.5g twice daily for 3 days)
   • For mild forms of acute uncomplicated cystitis (ACSS score <=10), Canephron N was an effective and safe alternative
   • Conclusion: Canephron N allows reduced antibiotic use in mild uncomplicated cystitis

3. Post-surgical UTI Prophylaxis (PMID: 33131431)

   • Randomized trial comparing Canephron N to ciprofloxacin for prevention of postoperative lower UTIs after midurethral sling surgery
   • Published in Journal of Clinical Medicine, 2020

4. Review of 17 Clinical Studies (PMID: 24198879)

   • Comprehensive review of safety, tolerability, and effects of Canephron N across Eastern Europe and Central Asia
   • Covered UTI treatment and prophylaxis in adults and children, renal stone patients, and gestational disease
   • Out of 3,115 patients across studies, only one adverse effect (skin rash) was reported
   • Concluded that Canephron N is effective for UTI treatment and prophylaxis with reduced relapse rates

5. Kidney Stone Metaphylaxis (PMID: 31162895)

   • Study of 75 patients after surgical treatment of urinary stone disease
   • Examined changes in diuresis and calcium excretion with Canephron N
   • Demonstrated positive effects on spontaneous elimination of small urinary calcium stones (up to 0.7 cm)

6. Inflammatory Pain in Cystitis and Prostatitis (PMID: 31257118)

   • Preclinical study demonstrating that BNO 2103 (Canephron N extract) alleviates inflammatory pain in experimental cystitis and prostatitis models
   • Published in Phytomedicine, 2019

Evidence Limitations

• No large RCTs for lovage root as a standalone monotherapy
• Canephron N trials cannot isolate lovage root’s individual contribution from the three-herb combination
• The Phase III non-inferiority trial used a 15% margin, which some may consider generous
• Most standalone evidence is pharmacological (in vitro / animal) rather than clinical
• The irrigation therapy concept itself makes placebo-controlled trials methodologically challenging

Safety Profile

Adverse Effects

• Generally well-tolerated: No adverse effects are specifically documented for lovage root monotherapy at recommended doses
• Photosensitivity (theoretical concern): Due to the presence of furanocoumarins (bergapten, psoralen), photoactivation by UV radiation is a theoretical risk
  • A case report describes phytophotodermatitis from harvesting lovage (dermal contact with plant sap + sunlight) (PMID: 1395606)
  • The EMA assessment notes that phototoxicity concerns are “not supported by clinical data or pharmacovigilance signals to be relevant for oral use of lovage root as recommended in the monograph”
  • Nevertheless, intensive UV exposure and sunbathing should be avoided during therapy as a precaution
• Allergic reactions: Possible in patients allergic to Apiaceae (celery, carrot, fennel, parsley) family — cross-reactivity should be considered
• Contact dermatitis: Essential oils may cause contact dermatitis in sensitized individuals (topical exposure)

Contraindications

• Acute kidney disease or renal inflammation: Irrigation therapy is inappropriate and potentially harmful
• Pregnancy: Lovage root is considered likely unsafe in pregnancy; traditional reports suggest it may stimulate uterine contractions or promote menstruation (emmenagogue effect), posing a miscarriage risk
• Edema due to cardiac or renal insufficiency: Irrigation therapy requires high fluid intake (2+ liters/day), which is contraindicated in patients who need fluid restriction
• Known hypersensitivity to lovage or other Apiaceae family members

Drug Interactions

• No significant drug interactions have been formally documented for lovage root monotherapy
• Theoretical considerations: Potential additive effect with pharmaceutical diuretics; some sources suggest caution with anticoagulants due to coumarin content, though clinical significance is unsubstantiated

Pregnancy and Lactation

• Pregnancy Category D: Contraindicated in pregnancy due to traditional reports of emmenagogue and potential abortifacient activity
• Lactation: Insufficient safety data; not recommended during breastfeeding

Age Restrictions

• Not recommended for children under 12 years (EMA/HMPC)

Clinical Dosage

Standardized Dosage Forms

Key Products

• Canephron N (Bionorica SE): Coated tablets or oral solution containing lovage root extract + rosemary leaf extract + centaury herb extract; standard adult dose is 2 tablets (or 50 drops) three times daily
• Canephron Uno (Bionorica SE): Higher-dose formulation; 1 tablet three times daily
• Bladder and kidney teas (Blasen- und Nierentee): Traditional German diuretic tea blends containing lovage root in combination with other irrigation herbs (birch leaf, goldenrod, horsetail)
• Species diureticae: European Pharmacopoeia-grade diuretic tea blend including lovage root

Critical: Fluid Intake Requirement

• During irrigation therapy, patients must maintain fluid intake of at least 2 liters per day
• The therapeutic effect depends on the combination of aquaretic herb + high fluid volume
• Without adequate hydration, the irrigation therapy concept is incomplete and ineffective

Duration of Treatment

• Suitable for short- to medium-term use (days to several weeks)
• Consult a physician if symptoms persist beyond 2 weeks or worsen
• For Canephron N: 7-day treatment course in acute UTI trials; up to 30 days in prophylaxis studies
• Long-term use for stone prophylaxis under medical supervision

Sources

• EMA Assessment Report on Levisticum officinale Koch, radix (EMA/HMPC/71049/2007)
• Altmeyers Encyclopedia — Lovage Root Monograph
• Phthalides in the Essential Oil from Roots of Levisticum officinale (PMID: 17402120)
• Characterization and Antibacterial Activity of Phthalides from Levisticum officinale (PMC7667549)
• Coumarins of Lovage Roots — LC-MS Profile (PMID: 36676932)
• Non-Antibiotic Herbal Therapy (BNO 1045) vs. Fosfomycin Phase III Trial (PMID: 30231252)
• Canephron N vs. Ciprofloxacin for Acute Uncomplicated Cystitis (PMID: 30761786)
• Efficacy and Safety of Canephron N — Eastern Europe/Central Asia Review (PMID: 24198879)
• BNO 2103 Alleviates Inflammatory Pain in Experimental Cystitis and Prostatitis (PMID: 31257118)
• Canephron N After Surgical Treatment of Urinary Stone Disease (PMID: 31162895)
• Canephron N Post-Surgical UTI Prophylaxis RCT (PMID: 33131431)
• Photosensitivity from Harvesting Lovage — Case Report (PMID: 1395606)
• Drugs.com — Lovage Uses, Benefits & Dosage
• Herbal Reality — Lovage Benefits, Safety, Uses
• WebMD — Lovage Overview

Connections

• See Goldenrod and Birch Leaf for other irrigation therapy herbs approved by Commission E
• See Bearberry Uva Ursi for a urinary antiseptic herb (different mechanism: arbutin/hydroquinone vs. irrigation)
• See Horsetail for another traditional European diuretic herb
• See Rosemary for the second herb component of Canephron N
• Lovage root is pharmacologically related to other Apiaceae herbs containing phthalides, including Chinese Angelica (Angelica sinensis / Dong Quai) which shares ligustilide as a key constituent